-
公开(公告)号：US20120178917A1
公开(公告)日：2012-07-12
申请号：US13428352
申请日：2012-03-23
CPC分类号： C12N15/1048 , A61K38/00 , C07H21/02 , C12N15/115 , C12N2310/322 , C12Y304/21005 , C12Y304/21006 , C12Y304/21021 , C12Y304/21022
摘要： RNA aptamers and methods for identifying the same are disclosed. The RNA aptamers selectively bind coagulation factors, E2F family members, Ang1 or Ang2, and therapeutic and other uses for the RNA aptamers are also disclosed.
摘要翻译： 公开了RNA适体和鉴定其的方法。 RNA适体选择性结合凝血因子，E2F家族成员，Ang1或Ang2，以及用于RNA适体的治疗和其它用途。
-
公开(公告)号：US08586524B2
公开(公告)日：2013-11-19
申请号：US11789992
申请日：2007-04-26
IPC分类号： A61K38/00 , C12N15/115
CPC分类号： C12N15/1137 , C12N15/113 , C12N15/115 , C12N2310/321 , C12N2310/322 , C12N2310/3515 , C12Y304/21022 , C12N2310/3521
摘要： The biological activity of nucleic acid ligand is regulated (i.e. enhanced or inhibited) in vivo to produce a desired biological effect. This is accomplished through the administration of a modulator, or regulator, that changes the binding of the nucleic acid ligand for its target or that degrades or otherwise cleaves, metabolizes or breaks down the nucleic acid ligand while the ligand is still exerting its effect. Modulators of the present invention can be administered in real time as needed based on various factors, including the progress of the patient, as well as the physician's discretion in how to achieve optimal therapy. Thus, this invention provides for the first time a regulatable therapeutic regime in the course of nucleic acid ligand therapy.
-
公开(公告)号：US20130197065A1
公开(公告)日：2013-08-01
申请号：US13751623
申请日：2013-01-28
IPC分类号： C12N15/115
CPC分类号： C12N15/115 , A61K31/711 , A61K47/60 , A61K48/00 , C07H21/02 , C08G65/329 , C08L2203/02 , C12N2310/16 , C12N2310/321 , C12N2310/322 , C12N2310/351 , C12N2310/531 , C12N2310/3521
摘要： The invention provides improved nucleic acid ligands that inhibit coagulation and improved modulators of the nucleic acid ligands to provide ideal modulators of coagulation. These improved nucleic acid ligands and modulators are particularly useful for inhibiting coagulation in a host undergoing a therapeutic regime such as surgery or coronary artery bypass.
摘要翻译： 本发明提供改进的核酸配体，其抑制凝血和核酸配体的改进的调节剂以提供理想的凝血调节剂。 这些改进的核酸配体和调节剂特别可用于抑制经历诸如手术或冠状动脉旁路治疗方案的宿主中的凝血。
-
公开(公告)号：US20120277419A1
公开(公告)日：2012-11-01
申请号：US13457095
申请日：2012-04-26
IPC分类号： C07H21/00
摘要： A method for preparing a therapeutic pegylated oligonucleotide is described. The method involves synthesis, cleavage and purification steps designed to improve the efficiency whereby the therapeutic oligonucleotide may be prepared. Also described are methods for large scale preparation at the improved efficiency.
摘要翻译： 描述了制备治疗性聚乙二醇化寡核苷酸的方法。 该方法涉及设计用于提高治疗性寡核苷酸可以制备的效率的合成，切割和纯化步骤。 还描述了以提高的效率进行大规模制备的方法。
-
公开(公告)号：US08283330B2
公开(公告)日：2012-10-09
申请号：US12637467
申请日：2009-12-14
CPC分类号： C12N15/1137 , C12N15/113 , C12N15/115 , C12N2310/321 , C12N2310/322 , C12N2310/3515 , C12Y304/21022 , C12N2310/3521
摘要： The biological activity of nucleic acid ligand is regulated (i.e. enhanced or inhibited) in vivo to produce a desired biological effect. This is accomplished through the administration of a modulator, or regulator, that changes the binding of the nucleic acid ligand for its target or that degrades or otherwise cleaves, metabolizes or breaks down the nucleic acid ligand while the ligand is still exerting its effect. Modulators of the present invention can be administered in real time as needed based on various factors, including the progress of the patient, as well as the physician's discretion in how to achieve optimal therapy. Thus, this invention provides for the first time a regulatable therapeutic regime in the course of nucleic acid ligand therapy.
摘要翻译： 核酸配体的生物活性在体内被调节（即增强或抑制）以产生所需的生物效应。 这通过施用调节剂或调节剂来实现，该调节剂或调节剂改变核酸配体对其靶标的结合，或者在配体仍然发挥作用时降解或以其它方式切割，代谢或分解核酸配体。 本发明的调节剂可以根据各种因素，包括患者的进展以及医师在如何达到最佳治疗方面的酌处权，根据需要实时施用。 因此，本发明在核酸配体治疗过程中首次提供可调节的治疗方案。
-
公开(公告)号：US07858591B2
公开(公告)日：2010-12-28
申请号：US11925651
申请日：2007-10-26
CPC分类号： C12N15/1048 , A61K38/00 , C07H21/02 , C12N15/115 , C12N2310/322 , C12Y304/21005 , C12Y304/21006 , C12Y304/21021 , C12Y304/21022
摘要： RNA aptamers and methods for identifying the same are disclosed. The RNA aptamers selectively bind coagulation factors, E2F family members, Ang1 or Ang2, and therapeutic and other uses for the RNA aptamers are also disclosed.
-
公开(公告)号：US20100311820A1
公开(公告)日：2010-12-09
申请号：US12793572
申请日：2010-06-03
CPC分类号： C12N15/115 , C12N2310/113 , C12N2310/16 , C12N2310/315 , C12N2310/321 , C12N2310/351 , C12N2320/50 , C12N2310/3521
摘要： The present invention relates, in general, to a pharmacologic system to modulate the biology of platelets based upon a nucleic acid ligand that can interact with and modulate the activity of platelet glycoprotein GPVI to regulate platelet function. These nucleic acid ligands are also actively reversible using a modulator that inhibits the activity of the nucleic acid ligand to neutralize this pharmacologic effect and thereby restore GPVI function, including collagen binding, platelet adhesion, collagen-induced platelet activation, and collagen-induced platelet aggregation. The invention further relates to compositions comprising the nucleic acid ligand, the ligand and a modulator, methods to generate the nucleic acid ligand and its modulator, as well as methods of using these agents and compositions in medical therapeutic and diagnostic procedures.
摘要翻译： 本发明一般涉及基于可与血小板糖蛋白GPVI相互作用并调节血小板糖蛋白GPVI的活性以调节血小板功能的核酸配体调节血小板生物学的药理学系统。 这些核酸配体也可以使用抑制核酸配体的活性来中和这种药理作用并由此恢复GPVI功能的调节剂，包括胶原结合，血小板粘附，胶原诱导的血小板活化和胶原诱导的血小板聚集 。 本发明还涉及包含核酸配体，配体和调节剂的组合物，产生核酸配体及其调节剂的方法，以及在医学治疗和诊断程序中使用这些试剂和组合物的方法。
-
公开(公告)号：US20080207546A1
公开(公告)日：2008-08-28
申请号：US11925648
申请日：2007-10-26
CPC分类号： C12N15/1048 , A61K38/00 , C07H21/02 , C12N15/115 , C12N2310/322 , C12Y304/21005 , C12Y304/21006 , C12Y304/21021 , C12Y304/21022
摘要： RNA aptamers and methods for identifying the same are disclosed. The RNA aptamers selectively bind coagulation factors, E2F family members, Ang1 or Ang2, and therapeutic and other uses for the RNA aptamers are also disclosed.
摘要翻译： 公开了RNA适体和鉴定其的方法。 RNA适体选择性结合凝血因子，E2F家族成员，Ang1或Ang2，以及用于RNA适体的治疗和其它用途。
-
公开(公告)号：US07312325B2
公开(公告)日：2007-12-25
申请号：US09963827
申请日：2001-09-26
CPC分类号： C12N15/1048 , A61K38/00 , C07H21/02 , C12N15/115 , C12N2310/322 , C12Y304/21005 , C12Y304/21006 , C12Y304/21021 , C12Y304/21022
摘要： RNA aptamers and methods for identifying the same are disclosed. The RNA aptamers selectively bind coagulation factors, E2F family members, Ang1 or Ang2, and therapeutic and other uses for the RNA aptamers are also disclosed.
摘要翻译： 公开了RNA适体和鉴定其的方法。 RNA适体选择性结合凝血因子，E2F家族成员，Ang1或Ang2，以及用于RNA适体的治疗和其它用途。
-
公开(公告)号：US08318923B2
公开(公告)日：2012-11-27
申请号：US12793572
申请日：2010-06-03
IPC分类号： C07H21/04
CPC分类号： C12N15/115 , C12N2310/113 , C12N2310/16 , C12N2310/315 , C12N2310/321 , C12N2310/351 , C12N2320/50 , C12N2310/3521
摘要： The present invention relates, in general, to a pharmacologic system to modulate the biology of platelets based upon a nucleic acid ligand that can interact with and modulate the activity of platelet glycoprotein GPVI to regulate platelet function. These nucleic acid ligands are also actively reversible using a modulator that inhibits the activity of the nucleic acid ligand to neutralize this pharmacologic effect and thereby restore GPVI function, including collagen binding, platelet adhesion, collagen-induced platelet activation, and collagen-induced platelet aggregation. The invention further relates to compositions comprising the nucleic acid ligand, the ligand and a modulator, methods to generate the nucleic acid ligand and its modulator, as well as methods of using these agents and compositions in medical therapeutic and diagnostic procedures.
摘要翻译： 本发明一般涉及基于可与血小板糖蛋白GPVI相互作用并调节血小板糖蛋白GPVI的活性以调节血小板功能的核酸配体调节血小板生物学的药理学系统。 这些核酸配体也可以使用抑制核酸配体的活性来中和这种药理作用并由此恢复GPVI功能的调节剂，包括胶原结合，血小板粘附，胶原诱导的血小板活化和胶原诱导的血小板聚集 。 本发明还涉及包含核酸配体，配体和调节剂的组合物，产生核酸配体及其调节剂的方法，以及在医学治疗和诊断程序中使用这些试剂和组合物的方法。
-
-
-
-
-
-
-
-
-
搜索结果
32 条记录 (耗时 0.049 秒)
